Evidence map›Paper›PMID 26122130›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2015

Sustained dual drug delivery of anti-inhibitory molecules for treatment of spinal cord injury.

Thomas S Wilems, Shelly E Sakiyama-Elbert

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Regenerative Therapies for Spinal Cord Injury.Tissue engineering. Part B, Reviews · 2019
    Review
  12. Epac2 Elevation Reverses Inhibition by Chondroitin Sulfate ProteoglycansThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Thomas S WilemsDepartment of Biomedical Engineering, Washington University, St. Louis, MO 63130, United States.
Shelly E Sakiyama-ElbertDepartment of Biomedical Engineering, Washington University, St. Louis, MO 63130, United States. Electronic address: sakiyama@wustl.edu.
Washington University in St. Louis · US

Funding

FIBRIN BASED SCAFFOLDS FOR SPINAL CORD INJURYR01NS051454 · NINDS · WASHINGTON UNIVERSITY · PI SAKIYAMA-ELBERT, SHELLY ELESE · 2005 to 2013
$2.4M
NINDS NIH HHS R01 NS051454
6 · The paper itself

Abstract

Myelin-associated inhibitors (MAIs) and chondroitin sulfate proteoglycans (CSPGs) are major contributors to axon growth inhibition following spinal cord injury and limit functional recovery. The NEP1-40 peptide competitively binds the Nogo receptor and partially blocks inhibition from MAIs, while chondroitinase ABC (ChABC) enzymatically digests CSPGs, which are upregulated at the site of injury. In vitro studies showed that the combination of ChABC and NEP1-40 increased neurite extension compared to either treatment alone when dissociated embryonic dorsal root ganglia were seeded onto inhibitory substrates containing both MAIs and CSPGs. Furthermore, the ability to provide sustained delivery of biologically active ChABC and NEP1-40 from biomaterial scaffolds was achieved by loading ChABC into lipid microtubes and NEP1-40 into poly (lactic-co-glycolic acid) (PLGA) microspheres, obviating the need for invasive intrathecal pumps or catheters. Fibrin scaffolds embedded with the drug delivery systems (PLGA microspheres and lipid microtubes) were capable of releasing active ChABC for up to one week and active NEP1-40 for over two weeks in vitro. In addition, the loaded drug delivery systems in fibrin scaffolds decreased CSPG deposition and development of a glial scar, while also increasing axon growth after spinal cord injury in vivo. Therefore, the sustained, local delivery of ChABC and NEP1-40 within the injured spinal cord may block both myelin and CSPG-associated inhibition and allow for improved axon growth.

Indexed as

AnimalsChickensChondroitin ABC LyaseDelayed-Action PreparationsDrug Delivery SystemsFemaleFibrinLactic AcidMyelin ProteinsNeurogenesisPeptide FragmentsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRats, Long-EvansSpinal Cord InjuriesTissue ScaffoldsChondroitin ABC LyaseDelayed-Action PreparationsFibrinLactic AcidMyelin ProteinsNEP1-40 protein, humanPeptide FragmentsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerChondroitinase ABCControlled releaseLipid microtubesNEP1-40PLGA microspheres

Identifiers

PMID26122130
PMCPMC4691576
OpenAlexW1806924313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.